The HLA-DR2 Haplotype Causes an Earlier Age of Onset, But Does Not Affect Disease Severity, Cognition or Cerebral Atrophy in Multiple Sclerosis

2009 ◽  
Vol 16 (11) ◽  
pp. 1514
Author(s):  
A Van der Walt ◽  
J Stankovich ◽  
M Bahlo ◽  
BV Taylor ◽  
IAF Van der Mei ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Severity ◽  
Age Of Onset ◽  
Cerebral Atrophy ◽  
Affect Disease Severity

Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition

2010 ◽  
Vol 17 (3) ◽  
pp. 344-352 ◽  
Author(s):  
Anneke Van der Walt ◽  
J Stankovich ◽  
M Bahlo ◽  
BV Taylor ◽  
IAF Van der Mei ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Severity ◽  
Brain Atrophy ◽  
Age Of Onset ◽  
Allelic Variation ◽  
Cerebral Atrophy ◽  
Population Based ◽  
Clinical Disease ◽  
Multiple Sclerosis Disease ◽  
Relapsing Remitting

Background: HLA-DRB1*1501 (DR15) and other HLA class II alleles increase the risk of developing multiple sclerosis (MS). However, the contribution of genetic heterogeneity to the clinical course of MS remains controversial. We examined the influence of DR15 and other common DRB1 alleles (DRB1*01 (DR1), DRB1*03 (DR3) and DRB1*04 (DR4) on MS severity in a large, Australian, population-based cohort. Methods: We studied the association between common HLA-DRB1 alleles and genotypes and age of onset as well as three clinical disease severity descriptors: Multiple Sclerosis Severity Score, progression index), and the interval between the first and second attack in 978 patients with relapsing remitting MS and secondary progressive MS. We assessed cognition using the Symbol Digit Modalities Test in 811 patients and brain atrophy using the linear magnetic resonance imaging marker, the intercaudate ratio, in 745 patients. Results: Carrying DR15 significantly decreased the age of MS onset by 3.2 years in homozygotes and 1.3 years in heterozygotes. Carrying the HLA-DR15, -DR1, -DR3 or -DR4 alone or in combination did not affect clinical disease severity, cognition or cerebral atrophy. Conclusions: This study confirms that heterogeneity of HLA-DRB1 does not influence disease outcome in relapsing MS patients, with the exception of a younger age of onset in HLA-DR15 carriers.

Characterizing driving behaviors in multiple sclerosis: Cognition versus disease severity

2008 ◽  
Author(s):  
Valerie D. Weisser ◽  
Kevin Manning ◽  
Allison Blasco ◽  
Nicole Sesitito ◽  
Jocelyn Ang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Severity ◽  
Driving Behaviors

scholarly journals Cutting Edge: Mast Cells Regulate Disease Severity in a Relapsing–Remitting Model of Multiple Sclerosis

2011 ◽  
Vol 186 (6) ◽  
pp. 3294-3298 ◽  
Author(s):  
Blayne A. Sayed ◽  
Margaret E. Walker ◽  
Melissa A. Brown
Keyword(s):  
Multiple Sclerosis ◽  
Mast Cells ◽  
Disease Severity ◽  
Cutting Edge ◽  
Relapsing Remitting

scholarly journals Multiple sclerosis in Kenya: Demographic and clinical characteristics of a registry cohort

2021 ◽  
Vol 7 (2) ◽  
pp. 205521732110227
Author(s):  
Imran Jamal ◽  
Jasmit Shah ◽  
Peter Mativo ◽  
Juzar Hooker ◽  
Mitchell Wallin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Symptom Onset ◽  
Clinical Characteristics ◽  
Age Of Onset ◽  
Sub Saharan Africa ◽  
University Hospital ◽  
Tertiary Referral Hospital ◽  
Female Ratio ◽  
Sub Saharan ◽  
Neuro Imaging

Background Multiple Sclerosis (MS) is the leading cause of non-traumatic neurological disability in young adults. There is limited literature regarding the burden of MS in sub-Saharan Africa (SSA). Objective To describe the demographic and clinical characteristics of patients with MS (PwMS) presenting to a tertiary referral hospital in Nairobi. Methods We conducted a retrospective descriptive study for PwMS presenting to Aga Khan University Hospital, Nairobi from 2008–2018. Results 99 cases met the diagnostic criteria for MS with a male to female ratio of 1:4. Majority (68.7%) of PwMS were indigenous Africans with a mean age of onset of 30.7 years. Mean duration from symptom onset to first neuro-imaging was 5.04 years. Only 33% of patients had sensory symptoms at onset whereas 54.5% had vitamin D deficiency/insufficiency. Majority (79.5%) had relapsing remitting MS (RRMS) and 56.6% were initiated on disease modifying therapy (DMT). Only 21.2% of patients on DMT were non-compliant. Patients with RRMS were more likely to be initiated on DMT at our hospital (p < 0.001). Conclusion Clinical characteristics of these patients largely resemble those of other SSA cohorts and African American patients. There was a delay between symptom onset and neuroimaging. There were also issues with DMT compliance.

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

2016 ◽  
Vol 23 (8) ◽  
pp. 1157-1166 ◽  
Author(s):  
Hasnat Ahmad ◽  
Bruce V Taylor ◽  
Ingrid van der Mei ◽  
Sam Colman ◽  
Beth A O’Leary ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Severity ◽  
Severe Disease ◽  
Health Utility ◽  
Health State Utility ◽  
Health State ◽  
Utility Values ◽  
Health State Utility Values ◽  
Economic Analyses ◽  
The Impact

Background: The measurement of health state utility values (HSUVs) for a representative sample of Australian people with multiple sclerosis (MS) has not previously been performed. Objectives: Our main aim was to quantify the HSUVs for different levels of disease severities in Australian people with MS. Method: HSUVs were calculated by employing a ‘judgement-based’ method that essentially creates EQ-5D-3L profiles based on WHOQOL-100 responses and then applying utility weights to each level in each dimension. A stepwise linear regression was used to evaluate the relationship between HSUVs and disease severity, classified as mild (Expanded Disability Status Scale (EDSS) levels: 0–3.5), moderate (EDSS levels: 4–6) and severe (EDSS levels: 6.5–9.5). Results: Mean HSUV for all people with MS was 0.53 (95% confidence interval (CI): 0.52–0.54). Utility decreased with increasing disease severity: 0.61 (95% CI: 0.60–0.62), 0.51 (95% CI: 0.50–0.52) and 0.40 (95% CI: 0.38–0.43) for mild, moderate and severe disease, respectively. Adjusted differences in mean HSUV between the three severity groups were statistically significant. Conclusion: For the first time in Australia, we have quantified the impact of increasing severity of MS on health utility of people with MS. The HSUVs we have generated will be useful in further health economic analyses of interventions that slow progression of MS.

Sign in / Sign up

Export Citation Format

Share Document